Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
What does it do?
Viatris is a global pharmaceutical company that makes and sells drugs in two main categories: generic drugs (cheaper copies of expired brand-name medications) and specialty brand drugs for specific conditions. Think of them as a middleman between huge drug makers like Pfizer and patients—they buy the rights to drugs, manufacture them, and distribute them worldwide to hospitals and pharmacies. They operate in over 140 countries and make everything from common antibiotics to complex injectable medications.
Viatris is caught in a tough spot: generic drug prices keep falling as competition increases, while their specialty drug business hasn't grown fast enough to offset these losses. Investors are watching to see if the company can stabilize earnings and return to growth, because right now it's burning cash and losing money—that's a red flag in healthcare where investors expect steady, predictable profits.
How does it make money?
Viatris generated $14.3B in revenue last year from selling generic and specialty drugs globally. Their revenue comes from pharmacy chains, hospitals, and government health programs that buy their medications in bulk. However, the company reported a $3.5B net loss, meaning after paying all their costs—manufacturing, research, distribution, and debt—they had nothing left. This loss was largely driven by one-time charges and restructuring costs from integrating past acquisitions.
Why do investors care?
The investment case depends on Viatris successfully cutting costs and stabilizing its generic drug business while growing higher-margin specialty drugs and biosimilars (complex copy drugs that are harder to replicate). If management can return the company to profitability and slow revenue declines, the stock could appeal to value investors—it's currently cheap relative to peers. The bull case requires proof that past acquisition integration is complete and that cost-cutting actually improves margins.
Deep Dive
MemberA full investor briefing on Viatris Inc. — history, leadership, risks, and outlook.